Secretin and Cholecystokinin

Cholecystokinin cells

Cholecystokinin (CCK) is an important hormonal regulator of the digestive process. CCK cells are concentrated in the proximal small intestine, and hormone is secreted into the blood upon the ingestion of food. The physiological actions of CCK include stimulation of pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and induction of satiety. Therefore, in a highly coordinated manner, CCK regulates the ingestion, digestion, and absorption of nutrients. CCK is produced by two separate cell types: endocrine cells of the small intestine and various neurons in the gastrointestinal tract and central nervous system. Accordingly, CCK can function as either a hormone or a neuropeptide. This review focuses on the physiology of the CCK cell in the intestine and, in particular, on how the CCK cell is regulated to secrete its hormone product. The effects of ingested nutrients on the CCK cell and the intracellular messenger systems involved in controlling secretion are reviewed. A summary is provided of recent studies examining the electrophysiological properties of CCK cells and newly discovered proteins that act as releasing factors for CCK, which mediate feedback pathways critical for regulated secretion in the intact organism.

Cholecystokinin evokes vasopressin release from perfused hypothalamic-neurohypophyseal explants

Cholecystokinin (CCK) may have a transmitter/modulator role in the hypothalamic magnocellular neurosecretory system. In the rat, the supraoptic and paraventricular nuclei display high affinity binding for radiolabelled CCK. Exogenously applied CCK depolarizes supraoptic neurons, acting at postsynaptic CCK-B type receptors. The present study evaluated the ability for the sulfated octapeptide of CCK (CCK-8S), which is a predominate form of this peptide in brain, to evoke release of vasopressin from the neurohypophysis of intra-arterially perfused hypothalamic explants. 3 min applications of 1 microM CCK-8S through the intra-arterial perfusion medium prompted an elevation of vasopressin in samples taken from the neurointermediate lobe in 10 of 14 preparations. Vasopressin levels rose from undetectable baseline values to a peak of 29.5 +/- 6.7 pg/ml (mean +/- S.E.M). This response was dose-dependent and was abolished by pituitary stalk transection (5/5 explants). Locally applied CCK-8S (25-200 pmol) through bilateral infusions onto the ventral surface of the supraoptic nucleus also induced a dose-dependent release of vasopressin (5/7 explants). These observations suggest that CCK can act at receptors located on (or near) the somata of supraoptic nucleus neurons to induce neuronal discharges that are conducted to the neural lobe where they evoke release of vasopressin from neurohypophysial axon terminals.

Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists

We present here the pharmacological properties of 3 ureido-acetamide members of a novel family of non-peptide cholecystokinin-B (CCKB) receptor antagonists. RP 69758 (3-(3-[N-(N-methyl N-phenyl-carbamoylmethyl) N-phenyl-carbamoylmethyl] ureido)phenylacetic acid), RP 71483 ((E)-2-[3-(3-hydroxyiminomethyl phenyl) ureido] N-(8-quinolyl) N-[(1,2,3,4-tetrahydro 1-quinolyl)carbonylmethyl]acetamide) and RP 72540 ((RS)-2-[3-(3-[N-(3-methoxy phenyl) N-(N-methyl N-phenyl-carbamoylmethyl) carbamoylmethyl] ureido) phenyl] propionic acid) displayed nanomolar affinity for guinea-pig, rat and mouse CCKB receptors labelled with [3H]pCCK-8 or with the selective CCKB receptor ligand [3H]pBC264. RP 69758 and RP 72540 showed selectivity factors in express of 200 for CCKB versus CCKA receptors. All three compounds had also high affinity for gastrin binding sites in the stomach. The ureido-acetamides behaved as potent antagonists of CCK-8-induced neuronal firing in rat hippocampal slices in vitro, a functional model of brain CCKB receptor mediated responses. RP 69758 is also a potent gastrin receptor antagonist in vivo that dose dependently inhibits gastric acid secretion induced by i.v. injection of pentagastrin in the rat. None of the three ureido-acetamides, at concentrations up to 1 microM, significantly blocked CCK-8-evoked contractions of the guinea-pig ileum in vitro, a CCKA receptor bioassay. In ex vivo binding studies, i.p. administration of RP 69758 and RP 72540 resulted in a dose-dependent inhibition of [3H]pCCK-8 binding in mouse brain homogenate. However, the relative penetration of these ureido-acetamides into the forebrain after peripheral administration was below 0.01%. RP 71483 did not appear to cross the blood-brain barrier in quantities sufficient to prevent [3H]pCCK-8 binding at low doses, a property that makes it suitable for the exploration of the peripheral versus central origin of the behavioural effects observed following systemic administration of CCK. RP 69758, RP 71483 and RP 72540 are highly potent and selective non-peptide CCKB receptor antagonists which are useful tools to explore the physiological functions of CCKB receptors.

The relationship of plasma cholecystokinin levels to different feeding routines in newborn infants

Plasma cholecystokinin concentrations were measured with radioimmunoassay in breast fed infants in Sweden (n = 101) and formula fed infants in Italy (n = 119). Blood samples were collected from the infants during the first five postnatal days, just before feeding in a cross-sectional way. We found no significant difference in the hormone concentration in relation to age, in breast fed or in formula fed infants. Breast fed infants had significantly higher plasma hormone concentrations than formula fed infants during the postnatal period 0-5 days: 2.8 pmol/l (1-10 pmol/l), median (range) versus 2.2 pmol/l (1-25 pmol/l), (P < 0.02). It cannot be excluded that the results were influenced by the circumstances that the samples were collected from two separate populations. However, the higher hormone levels in breast fed infants may also be the expression of the fact that natural feeding per se promotes cholecystokinin secretion in newborn infants.